Stock News and Filings Feed


Add HBP
to your dashboard

Helix Biopharma Corp. to Present at Third CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference

2017-07-31 marketwired
TORONTO, ONTARIO--(Marketwired - July 31, 2017) - Helix BioPharma Corp. (TSX:HBP)(FRANKFURT:HBP) ("Helix" or the "Company"), a clinical stage immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, is pleased to announce that the Company's poster entitled: "Immune checkpoint modulation by urease-mediated alkalization", has been accepted for presentation in the "Checkpoint Blockade Therapy" session at the Third International Cancer lmmunotherapy Conference.

Helix BioPharma Corp. Initiates Enrollment in the Third Dosing Cohort of U.S. Combination Treatment Study of Its Lung Cancer Drug Candidate L-DOS47

2017-07-25 marketwired
TORONTO, ONTARIO--(Marketwired - July 25, 2017) - Helix BioPharma Corp. (TSX:HBP)(FRANKFURT:HBP) ("Helix" or the "Company"), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced the opening of patient screening in the third dosing cohort of its ongoing U.S. study of L-DOS47 in combination treatment with pemetrexed/carboplatin ("LDOS001").

Helix BioPharma Corp. and Moffitt Cancer Center to investigate L-DOS47 and checkpoint blockade

2017-07-19 marketwired
L-DOS47 therapy provides an alternative pharmacologic approach to neutralizing tumor acidity that may improve the response of immune checkpoint inhibitors

Helix BioPharma Corp. Director Resigns

2017-07-17 marketwired
TORONTO, ONTARIO--(Marketwired - July 17, 2017) - Helix BioPharma Corp. (TSX:HBP)(FRANKFURT:HBP) ("Helix" or the "Company"), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced that the Board has accepted Mr. Albert Beraldo's resignation as director of the Company and Audit Committee Chair, effective July 14, 2017. Mr. Beraldo has conveyed to the Board that his other commitments have become too great for him to be able to fulfill the requirements of his position on the Board and determined it best for him to step down and make room for someone with the time and energy to devote to the Board and the Company.

Helix BioPharma Corp. Announces Collaboration with Moffitt Cancer Center

2017-07-11 marketwired
Helix to team up with Dr. Robert Gillies, Director of Moffitt's Cancer Imaging and Technology Center of Excellence on a research project aimed at extracting radiomics features from CT scans of late-stage lung cancer patients treated with L-DOS47

Helix BioPharma Corp. Announces Fiscal Third Quarter 2017 Results

2017-06-13 marketwired
TORONTO, ONTARIO--(Marketwired - June 13, 2017) - Helix BioPharma Corp. (TSX:HBP)(FRANKFURT:HBP) ("Helix" or the "Company"), a clinical stage immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, announces its financial results for its fiscal quarter ended April 30, 2017.

Helix BioPharma Corp. Closes Private Placement

2017-06-08 marketwired
TORONTO, ONTARIO--(Marketwired - June 7, 2017) - Helix BioPharma Corp. (TSX:HBP)(FRANKFURT:HBP) ("Helix" or the "Company"), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced it has closed a private placement financing for gross proceeds of approximately CAD3,028,800.

Helix BioPharma Corp. to Present at 3rd Annual Immuno-Oncology BD&L and Investment Forum

2017-05-30 marketwired
TORONTO, ON--(Marketwired - May 30, 2017) - Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP) ("Helix" or the "Company"), a clinical stage immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, is pleased to announce that company Chief Executive Officer and Chief Science Officer, Heman Chao, will be presenting at the upcoming 3rd Annual Immuno-oncology BD&L and Investment Forum ("IOBD&L") taking place on June 2nd, 2017 at the Hyatt Chicago Magnificent Mile Hotel.

Helix BioPharma Corp. Closes Private Placement

2017-04-27 marketwired
TORONTO, ON--(Marketwired - Apr 27, 2017) - Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP) ("Helix" or the "Company"), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced it has closed a private placement financing for aggregate gross proceeds of approximately CAD820,000.

Helix BioPharma Corp. to Present CAR-T at AACR Annual Meeting 2017 in Washington, D.C.

2017-04-03 marketwired
CAR-T cell harboring a camelid single domain antibody as a targeting agent to kill tumours expressing VEGFR2

Helix BioPharma Corp. Announces Fiscal Second Quarter 2017 Results and Closing of Private Placement

2017-03-17 marketwired
TORONTO, ONTARIO--(Marketwired - March 17, 2017) - Helix BioPharma Corp. (TSX:HBP)(FRANKFURT:HBP) ("Helix" or the "Company"), a clinical stage immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, announces its financial results for its fiscal quarter ended January 31, 2017.

Helix BioPharma Corp. Announces Strategic Management Changes

2017-03-07 marketwired
TORONTO, ON--(Marketwired - Mar 7, 2017) - Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP) ("Helix" or the "Company"), a clinical stage immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, announces that Dr. Sven Rohmann, CEO and Chairman of the Company, will be stepping down from his position as Chief Executive Officer of Helix BioPharma Corp.

Helix CEO to Step Down, Effective March 31

2017-03-07 biospace
TORONTO, ON--(Marketwired - Mar 7, 2017) - Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP) ("Helix" or the "Company"), a clinical stage immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, announces that Dr. Sven Rohmann, CEO and Chairman of the Company, will be stepping down from his position as Chief Executive Officer of Helix BioPharma Corp.

Helix BioPharma Corp. Announces Licence for Worldwide Right to Anti-CEACAM6 Antibody From the Government of Canada

2017-02-27 marketwired
TORONTO, ON--(Marketwired - Feb 27, 2017) - Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP) ("Helix" or the "Company"), a clinical stage immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, is pleased to announce that it has completed a licence agreement with the National Research Council of Canada ("NRC") for the worldwide right to anti-CEACAM6 antibody 2A3 for oncology applications.

30Mil CAD$ Investment in European Centre of Cancer Immunotherapy

2017-02-22 marketwired
TORONTO, ON--(Marketwired - Feb 22, 2017) - Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP) ("Helix" or the "Company"), a clinical stage immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, announces that Helix Immuno-Oncology ("HIO") has signed a non-binding letter of intent with KEN Poland Limited Liability Partnership ("KEN POLAND") in support of the European Centre for Cancer Immunotherapy ("ECCI").

Helix BioPharma Corp. Announces Voting Results from Its Annual and Special Meeting of Shareholders

2017-01-17 marketwired
TORONTO, ONTARIO--(Marketwired - Jan. 17, 2017) - Helix BioPharma Corp. (TSX:HBP) (FRANKFURT:HBP) ("Helix"), a clinical stage immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, announced today the results of matters voted on at its annual and special meeting of shareholders held on January 17, 2017 (the "Meeting").

Helix BioPharma Corp. Announces Fiscal First Quarter 2017 Results

2016-12-14 marketwired
TORONTO, ONTARIO--(Marketwired - Dec. 13, 2016) - Helix BioPharma Corp. (TSX:HBP)(FRANKFURT:HBP), an immuno-oncology company developing drug candidates for the prevention and treatment of cancer, today announced its financial results for the quarter ended October 31, 2016.